Comparison · NCT04222712-ee522ed1
TRS01 Low Dose vs TRS01 High Dose: Assessment of Both Systemic and Ocular Adverse Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TRS01 Low Dose vs TRS01 High Dose: Assessment of Both Systemic and Ocular Adverse Events. Trial comparisons, record NCT04222712-ee522ed1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04222712-ee522ed1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.25 | 0.0715 | 0.591 | wilson | |
| Risk in group 2 | 0.625 | 0.306 | 0.863 | wilson | |
| Risk difference, group 1 minus group 2 | -0.375 | -0.673 | 0.0919 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.4 | 0.107 | 1.49 | log | |
| Odds ratio, group 1 over group 2 | 0.2 | 0.0234 | 1.71 | log | |
| Number needed to treat, for one fewer participant with the outcome on TRS01 Low Dose than on TRS01 High Dose | 2.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TRS01 Low Dose | TRS01 eye drops: Dosed four times a day (QID) | 2 | 8 | OG000 |
| Group 2 | TRS01 High Dose | TRS01 eye drops: Dosed four times a day (QID) | 5 | 8 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Assessment of Both Systemic and Ocular Adverse Events
- Description
- Number of patients experiencing Adverse Events during the study
- Time frame
- 10 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis
- NCT number
- NCT04222712
- Phases
- PHASE1, PHASE2
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- TRS01 eye drops, TRS01 eye drops
- Lead sponsor
- Tarsier Pharma
- Results first posted
- 2023-10-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04222712?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04222712-ee522ed1